Keros Therapeutics, Inc. Stock Price, News & Analysis

Keros Therapeutics (KROS) announced preliminary clinical data from the Part 2 multiple ascending dose portion of its Phase 1 trial of KER-012, presented at the American Society of Bone and Mineral Research annual meeting on September 11, 2022. The results indicate that KER-012 effectively inhibits activin signaling, evidenced by a 52% reduction in follicle-stimulating hormone levels and significant increases in bone-specific alkaline phosphatase markers. No clinically meaningful changes were noted in hemoglobin or red blood cells. Keros plans to initiate a Phase 2 trial for KER-012 in pulmonary arterial hypertension patients in early 2023.

Keros Therapeutics, Inc. (Nasdaq: KROS) announced participation in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, at 3:40 PM ET. CEO Jasbir S. Seehra, Ph.D., and CFO Keith Regnante will discuss the company's innovative treatments aimed at hematological, pulmonary, and musculoskeletal disorders. A live audio webcast will be available, and an archived replay can be accessed for 90 days on Keros' website. Keros focuses on developing therapies like KER-050, KER-047, and KER-012 for various medical needs.

Keros Therapeutics (Nasdaq: KROS) announced two abstracts from its KER-012 and KER-050 programs will be presented at the ASBMR 2022 Annual Meeting in Austin, Texas, from September 9-12, 2022. The oral presentation on KER-012 will discuss its tolerability and its potential bone anabolic effects, scheduled for September 11, 2022. Additionally, a poster presentation on KER-050 will cover its efficacy in improving bone loss in a mouse model of myelodysplastic syndrome, also on September 11, 2022.

Keros Therapeutics reported positive clinical data for KER-050 and KER-012, showcasing their potential in treating hematological disorders. In the Phase 2 study for KER-050, 44% of high transfusion burden patients achieved transfusion independence. KER-012 demonstrated favorable safety and biomarker improvements in healthy volunteers. Keros strengthened its cash position, extending its runway to Q3 2024. However, the company reported a net loss of $27.3 million for Q2 2022, up from $15.6 million in Q2 2021, attributed to increased R&D and infrastructure costs.

Keros Therapeutics, Inc. (Nasdaq: KROS) announced promising results from a preclinical study of RKER-012 for pulmonary arterial hypertension (PAH) at the Pulmonary Hypertension Association Conference (June 10-12, 2022). RKER-012, an Activin Receptor Type IIB ligand trap, significantly reduced cardiac and pulmonary pathology in a rodent model, leading to lower Fulton index and systolic pulmonary arterial pressure (sPAP) compared to the control. These results suggest RKER-012 could potentially mitigate PAH-related damage to the heart and lung tissues.

Keros Therapeutics (KROS) announced new data from its ongoing Phase 2 trial of KER-050, targeting myelodysplastic syndromes (MDS), presented at the EHA Congress. The trial showed 51.9% of evaluable patients achieved an overall erythroid response. Part 2 of the trial has begun with a starting dose of 3.75 mg/kg, allowing for escalation to 5.0 mg/kg. KER-050 displayed a favorable safety profile with no serious adverse events reported. Keros also shared preclinical findings on KER-050's potential effects on thrombopoiesis and anemia treatment, suggesting a strong basis for further development.

Keros Therapeutics, Inc. (Nasdaq: KROS) reported preliminary topline results from Part 1 of its Phase 1 clinical trial for KER-012, aimed at treating bone-related disorders. The trial involved 32 healthy postmenopausal subjects receiving varying doses of KER-012. Results indicate KER-012 was generally well tolerated up to the highest tested dose of 5 mg/kg, with no serious adverse events reported. Key findings include a 39.6% reduction in follicle-stimulating hormone after a single high dose and significant increases in bone formation markers. Part 2 is ongoing, with data expected in H2 2022.

Keros Therapeutics (Nasdaq: KROS) announced promising results from a preclinical study of RKER-012 for treating pulmonary arterial hypertension (PAH) at the ATS International Conference. RKER-012 effectively prevented increases in pulmonary arterial pressure and right ventricle hypertrophy in a rodent model. In a separate study, KER-012 did not increase red blood cell levels in cynomolgus monkeys. These findings suggest that KER-012 may offer a safer treatment option for PAH without dose-limiting side effects. The company emphasizes KER-012's potential in treating PAH without adversely affecting red blood cell counts.

Keros Therapeutics, Inc. (Nasdaq: KROS) announced the presentation of three abstracts from its KER-050 and ALK2 hematology programs at the 27th Annual Congress of the European Hematology Association (EHA) from June 9-17, 2022. The abstracts include a Phase 2 study on KER-050 for anemia treatment in myelodysplastic syndromes, along with two preclinical studies related to platelet production and anemia of inflammation. KER-050 aims to address low blood cell counts in patients suffering from significant hematological disorders.